Precision Gear · The Slow Drip Rule · Dosing Accuracy
Administration Routes · Compound Reference · Storage
This document is for educational and research purposes only. It does not constitute medical advice and should not be used to guide human health decisions. Consult a qualified medical professional before beginning any protocol. All compound references reflect general research frameworks, not instructions for human use. The author assumes no responsibility for misuse. Users must comply with all applicable laws and regulations.
Your vial size and BAC water go in. Your exact units to draw come out. 26 compounds. Takes 30 seconds.
Use the Peptide CalculatorThe point of the gear list is not to sound technical. It is to reduce avoidable errors. Most dosing confusion starts before a vial is ever mixed, because the wrong tool changes the handling, the pressure, and the accuracy of the entire setup.
A 29G insulin-style needle is commonly used because it balances control and stopper preservation. It is narrow enough to reduce unnecessary damage to the vial top, but still practical for pressure handling. Thinner needles such as 31G can struggle with pressure equalization in some vial configurations, which is a handling problem, not a universal rule.
A 3mL syringe makes the water transfer easier to read and easier to control. It also reduces the temptation to use the same small dosing syringe for both reconstitution and administration math. That matters because the tool used to mix should not also be the tool used to read micro-dose units.
Whenever possible, draw the full BAC water amount once and complete the reconstitution in one controlled entry. Fewer punctures means less stopper wear, less handling error, and a cleaner process. Repeated tiny entries create more opportunities for pressure problems and contamination risk.
For multi-use vials, bacteriostatic water is generally preferred because the benzyl alcohol helps limit bacterial growth over time. Sterile water is not the same thing. It may be acceptable in some single-use research contexts, but for a vial that will be used repeatedly, BAC water is usually the cleaner and more practical choice.
Lyophilized powder looks stable because it is dry. The moment water is introduced, handling matters. Research suggests aggressive water contact with the lyophilized puck may disrupt peptide chain integrity and reduce potency. That does not mean one fast push automatically destroys a vial. It means the cleaner method is still the rational method.
Pull in a small amount of air first so the vial does not fight the transfer. Pressure issues make people push too hard.
Angling the vial gives the solution a glass wall to travel down instead of letting it hit the powder directly.
Do not blast water onto the puck. The goal is to let the liquid run down the side and settle gradually.
The right speed feels almost boring. Slow transfer gives the solution time to spread without turning the reconstitution into turbulence.
Avoid hard shaking. Gentle swirling or light rolling is typically used to let the powder dissolve while preserving structure.
This is the biggest math error in the category. If the water amount changes, every unit line changes. A correct vial amount with the wrong water amount still produces the wrong syringe read.
For single use it may sound interchangeable, but for a multi-use vial the contamination logic is different. The issue is not the word sterile. The issue is repeated entry over time.
Hard shaking is usually a sign the process got rushed. Gentle movement is the cleaner standard.
Most reconstituted peptides are treated as refrigerated materials. Leaving them out adds avoidable degradation risk and shortens useful life.
The syringe used to read 5, 10, or 20 unit pulls should not be the same tool used to transfer the full reconstitution volume. That is how small-scale reading errors get baked in from the start.
On a standard U-100 insulin syringe, 100 units equals 1mL. Beginners often confuse units with milliliters — they are not separate systems. Units are simply the syringe marking system on that 1mL scale. If the concentration is known, the unit line tells you how much liquid volume you are pulling. The compound dose depends on concentration. The syringe does not know the dose. It only knows the liquid amount.
| Vial Size | BAC Water | Dose | Draw (U-100) | Doses / Vial |
|---|---|---|---|---|
| 2 mg | 2.0 mL | 100 mcg | 10 units | 20 |
| 2 mg | 2.0 mL | 200 mcg | 20 units | 10 |
| 5 mg | 2.0 mL | 250 mcg | 10 units | 20 |
| 5 mg | 2.0 mL | 500 mcg | 20 units | 10 |
| 10 mg | 2.0 mL | 500 mcg | 10 units | 20 |
| 10 mg | 2.0 mL | 1 mg (1000 mcg) | 20 units | 10 |
| 15 mg | 2.0 mL | 1.5 mg | 20 units | 10 |
| 20 mg | 2.0 mL | 1 mg (1000 mcg) | 10 units | 20 |
| 20 mg | 2.0 mL | 2 mg | 20 units | 10 |
| Peptide | Eff. Dose Ref. | Frequency | BAC Vol | Vol / Dose | Days / Vial | Min Cycle | Max Cycle |
|---|---|---|---|---|---|---|---|
| AOD-9604 (10mg) | 350 mcg | 1x/day | 2.0mL | 0.7mL / 7u | 28 | 28d | 56d |
| BPC-157 (5mg) | 250 mcg | 1x/day | 1.5mL | 0.075mL / 7.5u | 20 | 14d | 56d |
| CJC-1295 No DAC (5mg) | 100–200 mcg | 2x/day | 2.0mL | 0.04mL / 4u | 25 | 28d | 56d |
| CJC-1295 No DAC (10mg) | 100–200 mcg | 2x/day | 2.0mL | 0.02mL / 2u | 50 | 100d | 100d |
| DSIP (5mg) | 300 mcg | 1x/night | 1.5mL | 0.09mL / 9u | 16.7 | 14d | 42d |
| Epithalon (10mg) | 5–10 mg | 1x/day | 2.0mL | 0.10mL / 10u | 2–4 | 10d | 20d |
| GHK-Cu (50mg) | 2 mg | 1x/day | 5.0mL | 0.20mL / 20u | 25 | 28d | 56d |
| GHRP-6 (10mg) | 100 mcg | 2x/day | 2.0mL | 0.02mL / 2u | 50 | 28d | 56d |
| Gonadorelin (2mg) | 100 mcg | 2x/week | 2.0mL | 0.10mL / 10u | 20 | 8w | 16w |
| HCG (5,000 IU) | 500 IU | 2x/week | 5.0mL | 0.50mL / 50u | 35 | 28d | 56d |
| Ipamorelin (5mg) | 200 mcg | 2x/day | 2.0mL | 0.08mL / 8u | 12.5 | 28d | 56d |
| Ipamorelin (10mg) | 200 mcg | 2x/day | 2.0mL | 0.04mL / 4u | 25 | 28d | 56d |
| KPV (10mg) | 250–500 mcg | 1x/day | 2.0mL | 0.05mL / 5u | 20–40 | 28d | 56d |
| LL-37 (5mg) | 100–200 mcg | 1x/day | 1.5mL | 0.04–0.08u | 25–50 | 14d | 28d |
| MOTS-c (10mg) | 500 mcg | 1x/day | 2.0mL | 0.10mL / 10u | 20 | 28d | 56d |
| NAD+ (500mg) | 50 mg | 2x/week | 5.0mL | 0.50mL / 50u | 35 | 28d | 56d |
| Oxytocin (2mg) | 0.15 mg | 1x/day | 2.0mL | 0.15mL / 15u | 13.3 | 28d | 56d |
| PT-141 (10mg) | 1.25 mg | 2x/week | 2.0mL | 0.25mL / 25u | 28 | 14d | 56d |
| Retatrutide (5mg) | 1 mg | 2x/week | 1.0mL | 0.20mL / 20u | 17.5 | 28d | 84d |
| Retatrutide (10mg) | 1 mg | 2x/week | 2.0mL | 0.20mL / 20u | 35 | 28d | 84d |
| Retatrutide (15mg) | 1 mg | 2x/week | 3.0mL | 0.20mL / 20u | 52.5 | 28d | 84d |
| Retatrutide (20mg) | 1 mg | 2x/week | 3.0mL | 0.15mL / 15u | 70 | 28d | 84d |
| Semax (10mg) | 300 mcg | 2x/day | 1.0mL | 0.03mL / 3u | 16 | 14d | 28d |
| Selank (10mg) | 300 mcg | 2x/day | 1.0mL | 0.03mL / 3u | 16 | 14d | 28d |
| SS-31 (5mg) | 1–2 mg | 1x/day | 2.0mL | 0.40mL / 40u | 5–10 | 14d | 28d |
| TB-500 (5mg) | 2 mg | 1x/week | 2.0mL | 0.80mL / 80u | 6.25 | 28d | 56d |
| Tesamorelin (5mg) | 1 mg | 1x/day | 2.5mL | 0.50mL / 50u | 5 | 28d | 56d |
| Tesamorelin (10mg) | 1 mg | 1x/day | 2.5mL | 0.25mL / 25u | 10 | 28d | 56d |
| Thymosin Alpha-1 (5mg) | 900 mcg | 2x/week | 2.0mL | 0.36mL / 36u | 13.9 | 28d | 84d |
| Wolverine Blend 10mg | 250 mcg ea. | 1x/day | 2.0mL | 0.10mL / 10u | 20 | 28d | 56d |
| Wolverine Blend 20mg | 250 mcg ea. | 1x/day | 2.0mL | 0.05mL / 5u | 40 | 28d | 56d |
All values are general research reference ranges only. Not dosing instructions for human use. Frequency and cycle data reflect commonly studied parameters in available literature.
Your vial size and BAC water go in. Your exact units to draw come out. 26 compounds. Concentration, doses per vial, cycle planning. Takes 30 seconds.
Use Peptide Calculator project-theo.com/pages/protocol-intelligence-toolCompounds below are organized by how they are most commonly administered in research contexts. Some appear in more than one category because research has studied them via multiple routes with different effects at each site. All dose ranges reflect general research reference data and are not instructions for human use.
These compounds are typically drawn from a reconstituted vial using a U-100 insulin syringe and injected into subcutaneous (under-skin) tissue, commonly abdomen or thigh.
| Compound | Research Dose Range | Frequency | Primary Mechanism (plain English) |
|---|---|---|---|
| AOD-9604 | 250–500 mcg | Daily / fasted | Fragment derived from the GH sequence studied for fat mobilization logic rather than GH replacement. |
| BPC-157 | 250–500 mcg | 1–2x/day | Studied for gut lining support and local tissue repair signaling, especially where inflammation or soft tissue stress is part of the picture. |
| CJC-1295 (No DAC) | 100–300 mcg | 1–2x/day, fasted | A GHRH analog studied to support the body's own GH pulse rather than supplying external growth hormone. |
| DSIP | 100–300 mcg | Nightly | Commonly researched for sleep architecture support, especially when deep sleep quality appears to be the limiting variable. |
| Epithalon | 5–10 mg | Nightly / split | Studied for pineal and melatonin-related signaling, usually in longevity-focused research rather than acute physique use. |
| GHK-Cu | 1–2 mg | Daily / several x/wk | Copper peptide studied for tissue quality, skin remodeling, and repair signaling rather than fat loss directly. |
| GHRP-6 | 100–300 mcg | 1–3x/day, fasted | A ghrelin receptor agonist studied to amplify GH release, but also known for producing a more obvious hunger signal. |
| Gonadorelin | 100–300 mcg | 2–3x/week | Studied for hypothalamic pituitary gonadal axis signaling where suppression, flat mood, and low drive are part of the case. |
| HCG | 250–500 IU | 2–3x/week | Studied for testicular signaling support in hormone axis research. Not a peptide but commonly grouped with peptide support protocols. |
| Ipamorelin | 100–300 mcg | 1–2x/day, fasted | Ghrelin mimetic studied to amplify GH pulse signaling with less appetite drive than older GHRPs. |
| Kisspeptin-10 | 100–300 mcg | 2–3x/week | Studied for upstream reproductive hormone signaling and hypothalamic control rather than direct body composition effects. |
| KPV | 250–500 mcg | 1–2x/day | Short anti-inflammatory peptide commonly studied where gut irritation and systemic inflammatory signaling overlap. Also oral. |
| LL-37 | 100–250 mcg | Daily / several x/wk | Antimicrobial peptide studied in immune and wound-related research, usually with more caution than standard repair peptides. |
| MOTS-c | 5–15 mg | 2–3x/week | Mitochondrial signaling peptide studied for energy handling and AMPK-related adaptation rather than appetite suppression. |
| NAD+ | 25–100 mg | 2–5x/week | Redox cofactor studied as cellular fuel support when fatigue and output capacity are part of the bottleneck. |
| Oxytocin Acetate | 100–300 mcg | As scheduled | Studied for social bonding, stress regulation, and sometimes appetite-related signaling. Context matters heavily here. |
| PT-141 (Bremelanotide) | 0.5–2 mg | As needed | Melanocortin agonist studied mainly for arousal signaling, not as a body composition tool. Also intranasal. |
| Retatrutide | 1–8 mg | Weekly | Triple agonist studied for intake control plus output pressure through glucagon signaling, which changes how hunger and heat are interpreted. |
| Semax | 300–900 mcg | Daily / split | Nootropic peptide researched for cognitive signaling. Some setups study subcutaneous delivery alongside the more common intranasal route. |
| Selank | 250–500 mcg | Daily / split | Anxiolytic peptide more often studied intranasally, with subcutaneous use appearing in some research contexts. |
| SS-31 (Elamipretide) | 5–20 mg | Daily | Mitochondrial peptide studied to stabilize inner membrane function when energy inefficiency, not appetite, is the actual problem. |
| TB-500 | 2–5 mg | Weekly / split | Systemic repair peptide studied for cell migration and recovery signaling across soft tissue and connective tissue contexts. |
| Tesamorelin | 1–2 mg | Daily | GHRH analog studied for stronger and more measurable GH pathway pressure, often when visceral fat and lean mass protection are central concerns. |
| Thymosin Alpha-1 | 0.5–1.5 mg | 2–3x/week | Immune signaling peptide studied when recovery, inflammation, and immune resilience overlap. |
| Wolverine Blend (BPC+TB-500) | Varies by blend | Daily + weekly | Combination used in repair-focused research to pair local gut and tissue signaling with broader systemic recovery support. |
Used most often in nootropic, anxiolytic, and certain specialty signaling contexts where fast, non-injectable delivery is part of the research setup.
| Compound | Research Dose Range | Frequency | Primary Mechanism |
|---|---|---|---|
| Semax | 300–900 mcg | Daily / split | Studied for BDNF-related cognitive signaling, especially where mental flatness and reduced focus are part of a larger recovery problem. |
| Selank | 250–500 mcg | Daily / split | Studied for stress and anxiety regulation without the sedation profile that many researchers are trying to avoid. |
| PT-141 (Bremelanotide) | 1–5 mg equiv. | Intermittent | Alternate delivery route for melanocortin signaling research, with the same basic mechanism but a different onset profile. |
| Oxytocin | 100–300 mcg | Intermittent / daily | Studied for bonding, calmness, and stress-related signaling. Interpretation depends heavily on context and intent. |
| Cerebrolysin | Protocol dependent | Protocol dependent | Often discussed in neural recovery circles. Intranasal discussion exists but evidence is uneven. Not a peptide in the narrow sense. |
| Dihexa | 5–20 mg | Daily | Research-stage cognitive compound discussed for synaptic and learning-related signaling. Still highly experimental with limited human data. |
| PE-22-28 | 400–1000 mcg | Daily | Experimental anxiolytic peptide discussed in nootropic communities with limited formal human data. |
| NA-1 (Nerinetide) | Protocol dependent | Acute / short block | Stroke and neuroprotection literature drives most discussion here. Not a casual peptide reference item. |
Oral entries are included because many researchers group them with peptide workflows even when the compound itself is not technically a peptide.
| Compound | Research Dose Range | Frequency | Notes |
|---|---|---|---|
| BPC-157 (oral form) | 250–1000 mcg | 1–2x/day | Oral form is usually studied for GI-targeted support rather than the more generalized repair logic often assumed from injectable use. |
| KPV | 250–1000 mcg | 1–2x/day | Oral use is usually discussed when gut inflammation is the leading issue rather than systemic performance problems. Also SubQ. |
| Larazotide (AT-1001) | 0.25–1 mg | 1–3x/day | Tight junction modulator studied in gut barrier research rather than physique applications. |
| MK-677 (Ibutamoren) | 10–25 mg | Daily | Not a peptide. Oral secretagogue studied for sustained GH and IGF-1 pathway stimulation through ghrelin receptor signaling. |
| SLU-PP-332 | 50–200 mcg (early discussion) | Daily — research stage | Research suggests ERR pathway activation may influence mitochondrial biogenesis and metabolic output. Human data remains extremely limited as of early 2026. |
Keep reconstituted vials refrigerated, protected from light, and handled as if every extra touch lowers the quality of the process. Clean stopper technique, fewer unnecessary entries, and calm handling matter more than people think because small mechanical errors compound over time.
Unconstituted peptides are commonly stored frozen for months and sometimes longer depending on the compound and handling quality. Once removed from the freezer, minimize temperature cycling before reconstitution.
Once reconstituted, most research setups treat 14 to 28 days refrigerated as the conservative window for most peptides, with certain compounds discussed as shorter or more fragile exceptions. Always confirm per compound.
Concentration errors and preparation errors create fake protocol problems. A researcher can misread a compound when the real problem was the mix, the syringe math, the storage, or the handling. That is why mechanics come first.
If a solution becomes cloudy without explanation, develops visible particles, changes color unexpectedly, or has been handled carelessly enough that confidence in sterility is gone, the rational move is not to force interpretation. Stop using that vial and reset the process.
Concentration errors and preparation errors create fake protocol problems. A researcher can misread a compound when the real problem was the mix, the syringe math, the storage, or the handling. That is why mechanics come first.
Answer a short set of questions about your current protocol. The tool identifies the most likely bottleneck and tells you what to look at first.
Find My Bottleneck project-theo.com/pages/protocol-toolThe reconstitution guide fixes preparation. It does not diagnose why a protocol stalled, why hunger changed, why energy collapsed, or why the stack got harder to interpret. That is exactly what the audit covers.
The Project Theo Metabolic and Peptide Protocol Audit is the next step when the setup is correct but the interpretation is still unclear. Every tier includes a full written report with no withheld sections.
project-theo.com